News
4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results
It's that time again, folks: Earnings season is kicking into full swing. And with that comes healthcare conglomerate Johnson & Johnson's (NYSE: JNJ) quarterly report, which often sets the tone for the
3 Small Biotech Stocks Being Run by Proven Winners
Great leaders are important in any industry, but perhaps they're even more valuable in biotech, where any number of clinical-stage and regulatory obstacles can derail drug research and send share
These 3 Stocks Have Doubled Investors' Money in 2017
The stock market has done well so far in 2017, with gains of almost 10% for the S&P 500 and even greater rises for some other major market benchmarks. A small number of top-performing stocks have done
Will the Drug Pricing Executive Order Help Big Pharma?
The cost of healthcare has climbed at a rate considerably above that of inflation, and high drug costs are a big factor. During his campaign, President Trump indicated that he would take steps to
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Pfizer (NYSE: PFE) stands at the top of the mountain when it comes to prescription drug sales. Last year, the big pharma company made $45.9 billion from prescription drugs, well ahead of runners-up
These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition
Pretty much everyone familiar with Gilead Sciences (NASDAQ: GILD) wants the company to make an acquisition. Many think the big biotech desperately needs one (or more) to reenergize the lethargic
Roundtable: 1 Stock I'm Never Selling
Stocks that are worth buying and holding for exceptionally long periods of time are far less common than most investors may think. Changes in underlying market conditions, after all, can knock even
Is It Too Late to Get In on This Millionaire-Maker Stock?
Corcept Therapeutics (NASDAQ: CORT) is one hot biotech stock no matter how you look at it. Shares have nearly quintupled in value in just three years. So far in 2017, Corcept stock is up around 70%.
Never Will I Ever Buy Preclinical Biotech Stocks. No Way!
It's "Never Will I Ever" week on Industry Focus, and we're explaining what we'll never invest in and why.It's incredibly difficult to develop new, game-changing medicine. How difficult? Over 90% of
Why You're Smart to Buy Vertex Pharmaceuticals Stock
You might look at Vertex Pharmaceuticals (NASDAQ: VRTX) stock and shake your head at its valuation. After soaring more than 70% so far in 2017, shares of the biotech now trade at a whopping 180 times
3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months
Although there is some truth in the saying that it takes money to make money, that doesn't mean investors can't start small and reap big rewards. With little more than $1,000 in your account, you can
Is Aurinia Pharmaceuticals' Management Its Best Asset?
Richard Glickman was the founder and CEO of Aspreva Pharmaceuticals, a small company that he sold for $915 million in 2008 after it developed CellCept, a treatment that today is commonly used in lupus
Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?
Despite a widespread rally across the biotech landscape last month, the struggling clinical-stage cancer company Celldex Therapeutics (NASDAQ: CLDX) still managed to shed 14.8% of its value in
Can Bellicum Pharmaceuticals Stock Bounce Back?
How you view a stock depends heavily on your point of reference. Bellicum Pharmaceuticals (NASDAQ: BLCM), for example, saw its share price fall nearly 14% in one day in late June. That's certainly not
5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals
There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there's the third type of marijuana stock: the
Is It Time to Sell Portola?
Portola Pharmaceuticals' (NASDAQ: PTLA) stock recently jumped 45% on the news that it won its first FDA approval.In this segment of Industry Focus: Healthcare, Motley Fool analyst Kristine Harjes and
No Surprise! Amicus Therapeutics Hits Up Investors for More Cash
Amicus Therapeutics (NASDAQ: FOLD) will be able to submit its Fabry disease drug Galafold to the FDA for consideration, a reversal of fortune that sent shares skyrocketing earlier this week. While
A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared
A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE: NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or
How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug
1 Reason Why Cara Therapeutics Ended June Down 11.3%
Cara Therapeutics (NASDAQ: CARA), a clinical-stage biotech developing treatments for pain and chronic kidney disease-associated pruritus (itching), gave investors an absolutely wild ride last month
Here's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back
Investors in Alder Biopharmaceuticals (NASDAQ: ALDR) are having another wild day. Shares of the clinical-stage biopharma rose as much as 15.5% on Thursday after the company released the pricing
Is Juno Therapeutics Stock Still a Strong Buy?
Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ: JUNO) rose by a healthy 22% last month, according to S&P Global Market Intelligence. The drugmaker's shares seemed to get a lift from
Johnson & Johnson Looks for Second-Quarter Strength to Keep Upward Momentum
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) has been immensely successful over the years, and it has also done well for shareholders recently. With a nearly 15% rise so far in 2017, Johnson
Portola's Hitting All-Time Highs: Here's Why the Stock Should Go Higher
Portola Pharmaceuticals' (NASDAQ: PTLA) won FDA approval of their first commercial drug, Bevyxxa in June, and that sent shares skyrocketing. Yet the market opportunity for Bevyxxa could total in the
Quantum Genomics annonce son inscription sur le marché américain OTCQX
Paris, le 11 juillet 2017
Quantum Genomics (Alternext - FR0011648971 - ALQGC), société biopharmaceutique dont la mission est de développer de nouvelles thérapies pour des besoins....
